Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357696 | 0.85 | ALDH1A1 (0.31) | MAPTALDH1A1HTTSMN1; SMN2ACHE | |
| SCHEMBL15301421 | 0.85 | ALDH1A1 (0.33) | MAPTALDH1A1HTTSMN1; SMN2ACHE | |
| SCHEMBL2869705 | 0.84 | ALDH1A1 (0.32) | MAPTALDH1A1HTTSMN1; SMN2APAF1 | |
| SCHEMBL5597843 | 0.84 | ALDH1A1 (0.30) | MAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL357534 | 0.83 | MAPT (0.32) | MAPTALDH1A1HTTSMN1; SMN2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL192398 | 0.83 | ACHE (0.40) | MAPTALDH1A1HTTSMN1; SMN2ACHE | |
| SCHEMBL357139 | 0.82 | ALDH1A1 (0.34) | MAPTALDH1A1HTTSMN1; SMN2ACHE | |
| Hydrochloric Acid SCHEMBL2872725 | 0.82 | MAPT (0.32) | MAPTALDH1A1HTTSMN1; SMN2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL28555818 | 0.81 | ACHE (0.40) | MAPTALDH1A1HTTSMN1; SMN2ACHE | |
| SCHEMBL1172288 | 0.81 | KDM4E (0.31) | MAPTALDH1A1HTTSMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021276-B1 | PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS | DU PONT (US) | 2013-07-17 | — | — | EP | claimed |
| US-20100143993-A1 | PROCESS FOR FERMENTIVE PREPARATIONFOR ALCOLHOLS AND RECOVERY OF PRODUCT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | US | claimed |
| US-20100143999-A1 | PROCESS FOR FERMENTIVE PREPARATION OF ALCOHOLS AND RECOVERY OF PRODUCT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | US | claimed |
| US-20100143994-A1 | PROCESS FOR FERMENTIVE PREPARATION OF ALCOHOLS AND RECOVERY OF PRODUCT | E. I. DU PONT DE MEMOURS AND COMPANY | 2010-06-10 | — | — | US | claimed |
| US-20100139154-A1 | PROCESS FOR FERMENTIVE PREPARATION OF ALCOHOLS AND RECOVERY OF PRODUCT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | US | claimed |
| US-20200129922-A1 | METHOD OF REDUCING CONCENTRATION OF FLUORINE-CONTAINING COMPOUND IN SAMPLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-04-30 | — | — | US | disclosed |
| US-8771626-B2 | Process for purifying perfluorinated products | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8715521-B2 | Absorption cycle utilizing ionic liquid as working fluid | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8707720-B2 | Hybrid vapor compression-absorption cycle | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8628644-B2 | Utilizing ionic liquids for hydrofluorocarbon separation | E I DU PONT NEMOURS AND COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-8568608-B2 | Vapor compression cycle utilizing ionic liquid as compressor lubricant | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2021276-B1 | PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS | DU PONT (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20070295478-A1 | Vapor Compression Cycle Utilizing Ionic Liquid as Compressor Lubricant | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-12-27 | — | — | US | disclosed |
| WO-2007143051-A2 | VAPOR COMPRESSION UTILIZING IONIC LIQUID AS COMPRESSOR LUBRICANT | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007143055-A2 | PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070131535-A1 | Utilizing ionic liquids for hydrofluorocarbon separation | THE CHEMOURS COMPANY FC, LLC | 2007-06-14 | — | — | US | disclosed |
| WO-2007038363-A2 | UTILIZING IONIC LIQUIDS FOR HYDROFLUOROCARBON SEPARATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070019708-A1 | Hybrid vapor compression-absorption cycle | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-01-25 | — | — | US | disclosed |
| WO-2006124776-A2 | HYBRID VAPOR COMPRESSION-ABSORPTION CYCLE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060197053-A1 | Absorption cycle utilizing ionic liquid as working fluid | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070131535-A1 | Utilizing ionic liquids for hydrofluorocarbon separation | AQP3, AQP1, SLC26A3 | MAPT 1618/4885ALDH1A1 1317/4885HTT 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.